SCHEMBL5046511

SCHEMBL5046511

CCCCCCSc1nc(C=O)cc(C2CC2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.37
LMNA P02545 2/20 0.37
MAPT P10636 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
GPR84 Q9NQS5 9/20 0.36
SCN9A Q15858 2/20 0.36
SCN5A Q14524 1/20 0.36
CHRM1 P11229 1/20 0.35
NPC1 O15118 1/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 1/20 0.34
ALPL P05186 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6021992 0.87 GPR84 (0.32) GPR84CHRM1
SCHEMBL5049080 0.81 GPR84 (0.49) SMN1; SMN2LMNAMAPTALDH1A1HPGD
SCHEMBL5049134 0.80 SMN1; SMN2 (0.39) SMN1; SMN2LMNAMAPTALDH1A1HPGD
SCHEMBL5049907 0.76 SMN1; SMN2 (0.38) SMN1; SMN2LMNAMAPTALDH1A1HPGD
SCHEMBL5045840 0.73 SMN1; SMN2 (0.35) SMN1; SMN2LMNAMAPTALDH1A1HPGD
SCHEMBL5691144 0.72 TLR8 (0.42) SMN1; SMN2LMNAMAPTALDH1A1HPGD
SCHEMBL5045978 0.72 GPR84 (0.50) SMN1; SMN2LMNAMAPTALDH1A1HPGD
SCHEMBL5046102 0.70 THRB (0.41) SMN1; SMN2ALDH1A1HPGDNPC1RAB9A
SCHEMBL5690816 0.68 BRAF (0.40) SMN1; SMN2LMNAMAPTALDH1A1HPGD
SCHEMBL10997188 0.66 SMN1; SMN2 (0.47) SMN1; SMN2LMNAMAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351700-B2 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. (US) 2008-04-01 US disclosed
EP-1725239-B1 4-(SULFANYL-PYRIMIDIN-4-YLMETHYL)-MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY HOFFMANN LA ROCHE (CH) 2007-07-18 EP disclosed
EP-1725239-A1 4-(SULFANYL-PYRIMIDIN-4-YLMETHYL)-MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY F.HOFFMANN-LA ROCHE AG (CH) 2006-11-29 EP disclosed
WO-2005094828-A1 4- (SULFANYL-PYRIMIDIN-4-YLMETHYL) -MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY F. HOFFMANN-LA ROCHE AG (CH) 2005-10-13 WO disclosed
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors CHRNA2, CNR2, GABRB2 SMN1; SMN2 98/4885LMNA 4113/4885MAPT 3045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.